They can't afford to wait or take the risk of extensions.
I would think there are three parts to their process The vector, the ddRNAi and the "novel" bit.
The fact they call it novel bifunctional shRNA tells me they will want a licence.
It's getting more expensive by the day.
Something from Gradalis or a hint of action from Cal1 will ignite the US interest many fold.
speaking of gradaiis, page-3
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)